Received Sep 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
got Guillain-Barre; This serious case was reported by a consumer via interactive digital media and described the occurrence of guillain barre syndrome in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced guillain barre syndrome (Verbatim: got Guillain-Barre) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome was resolved. It was unknown if the reporter considered the guillain barre syndrome to be related to Shingrix. The company considered the guillain barre syndrome to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 08-SEP-2025 This case was reported by a patient via (Shingles) interactive digital media. Reporter reported that vaccines destroying adult lives also. Patient now having extreme problems with peripheral neuropathy and other conditions.; Sender's Comments: A case of Guillain-Barre syndrome, on an unknown date after receiving the 1st dose of Shingrix, in a patient. Based on the available information a possible causality that the events were caused by GSK vaccine product cannot be ascertained. Consent for further follow up has not been received